Kidney Transplantation for IgA Nephropathy with End-Stage Kidney Disease
Yes, kidney transplantation is indicated for patients with IgA nephropathy who have reached end-stage kidney disease and are otherwise medically stable. Transplantation offers superior survival and quality of life compared to remaining on dialysis, despite the risk of disease recurrence in the allograft.
Rationale for Transplantation
Kidney transplantation is the preferred treatment for end-stage kidney disease caused by IgA nephropathy 1. While IgAN is the most common primary glomerulonephritis worldwide and progresses to end-stage disease in 20-40% of patients within 20 years 2, 3, transplantation provides:
- Superior survival outcomes: Compared to maintenance dialysis, successful transplantation significantly reduces mortality and improves quality of life 4
- Acceptable graft survival: Five-year graft survival rates range from 72% to 99%, with the best outcomes in living donor recipients 4
- Manageable recurrence risk: IgAN recurs in approximately 15-23% of transplanted kidneys at 10 years post-transplant 2, 5, 6, which is significantly lower than other glomerular diseases like FSGS (59.1% recurrence) 5
Key Clinical Considerations
Disease Recurrence
While recurrence occurs in 15-23% of cases over 10 years 2, 5, several important points mitigate this concern:
- Recurrence rarely causes immediate graft loss: Most recurrent disease progresses slowly 7, 8
- Graft function remains stable: Studies show eGFR remains high (65-68 mL/min/1.73m²) during medium- and long-term follow-up 7
- Overall graft survival exceeds 95% in contemporary series 7
Immunosuppression Strategy
Tacrolimus-based maintenance immunosuppression is preferred over cyclosporine, as it is associated with significantly lower rates of IgAN recurrence in the allograft 5. The standard triple immunosuppression regimen (tacrolimus, mycophenolate, and corticosteroids) should be used, with judicious corticosteroid dosing given potential complications 1.
Risk Stratification
Patients with high mesangial hypercellularity and segmental glomerulosclerosis on native kidney biopsy (Oxford classification) may have higher recurrence risk 6. However, this should not preclude transplantation, as outcomes remain favorable overall.
Transplant Timing and Preparation
- Refer early: Patients with advanced chronic kidney disease should be referred for transplant evaluation before reaching dialysis 1
- Living donor preferred: Living donor transplantation offers superior outcomes with graft survival rates approaching 99% at 5 years 4
- Protocol monitoring: Post-transplant surveillance should include regular proteinuria monitoring and consideration of protocol biopsies, as these detect recurrence earlier than clinical presentation alone 2, 8
Contraindications
The only absolute contraindication specific to IgAN would be active IgAN with monoclonal gammopathy of rheumatologic significance (MGRhS) with multi-system involvement 9. In such cases, complete elimination of the monoclonal protein before transplantation is critical for sustained allograft survival.
Post-Transplant Management
- Optimize supportive care: Continue RAS blockade (ACE inhibitors or ARBs) and consider SGLT2 inhibitors for renoprotection, as these reduce proteinuria and preserve graft function 10, 11
- Monitor for recurrence: Regular urinalysis, proteinuria quantification, and kidney function assessment
- Biopsy threshold: Consider allograft biopsy for unexplained proteinuria >0.5 g/day or rising creatinine 11
- Treatment of recurrence: If recurrence occurs with significant proteinuria, novel targeted therapies (budesonide, complement inhibitors) may be considered, though evidence in the post-transplant setting is limited 12, 13
The evidence strongly supports proceeding with kidney transplantation for medically stable patients with end-stage IgA nephropathy, as the benefits of transplantation substantially outweigh the risk of disease recurrence 1, 7, 5.